Morgan Stanley Novan, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.41 - $1.4 $984 - $3,362	-2,402 Reduced 30.59%	5,450 $2,000
Q1 2023 May 15, 2023	BUY	$1.05 - $2.04 $841 - $1,634	801 Added 11.36%	7,852 $10,000
Q4 2022 Feb 14, 2023	SELL	$0.82 - $1.48 $693 - $1,252	-846 Reduced 10.71%	7,051 $10,000
Q3 2022 Nov 14, 2022	BUY	$1.76 - $3.03 $174 - $299	99 Added 1.27%	7,897 $15,000
Q2 2022 Oct 27, 2022	SELL	$2.29 - $3.86 $48,225 - $81,287	-21,059 Reduced 72.98%	7,798 $18,000

Q2 2022 Aug 15, 2022	SELL	$2.29 - $3.86 $48,225 - $81,287	-21,059 Reduced 72.98%	7,798 $18,000
Q1 2022 Oct 27, 2022	BUY	$2.95 - $4.41 $62,124 - $92,870	21,059 Added 270.06%	28,857 $114,000
Q1 2022 May 13, 2022	BUY	$2.95 - $4.41 $10,481 - $15,668	3,553 Added 14.04%	28,857 $114,000
Q4 2021 Feb 14, 2022	SELL	$4.03 - $8.15 $6,931 - $14,018	-1,720 Reduced 6.36%	25,304 $106,000
Q3 2021 Nov 15, 2021	BUY	$7.48 - $10.17 $202,139 - $274,834	27,024 New	27,024 $219,000

Ticker NOVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,281,600
Market Cap $638K
Description
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-sp...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.